Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.58 |
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3724360 | 0.91 | HTT (0.68) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL6444986 | 0.89 | HTT (0.67) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL7283930 | 0.88 | TGM2 (0.65) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL7283534 | 0.88 | TGM2 (0.65) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL9222029 | 0.88 | TGM2 (0.65) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL7283765 | 0.88 | TGM2 (0.65) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL7285301 | 0.88 | TGM2 (0.65) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL3151115 | 0.88 | TGM2 (0.65) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL13055383 | 0.86 | LMNA (0.80) | LMNASMN1; SMN2HTTKEAP1NFE2L2 | |
| SCHEMBL708331 | 0.86 | LMNA (0.65) | LMNASMN1; SMN2HTTKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1262671-C | Novel enzyme substrates for the detection of Pseudomonas aeruginosa, compositions containing them, and methods for detecting this species | BIOMERIEUX SA (FR) | 2006-07-05 | — | — | CN | disclosed |
| CN-1216046-C | Improved methods of synthesis for 9-substituted hypoxanthine derivatives | MORK EPROWA AG (CH) | 2005-08-24 | — | — | CN | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| CN-1449387-A | Improved methods of synthesis for 9-substituted hypoxanthine derivatives | NEOTHERAPEUTICS INC (US) | 2003-10-15 | — | — | CN | disclosed |
| CN-1408026-A | Novel enzyme substrates for the detection of Pseudomonas aeruginosa, compositions containing them, and methods for detecting this species | BIOMERIEUX SA (FR) | 2003-04-02 | — | — | CN | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| WO-1999042099-A1 | LOW MOLECULAR WEIGHT COMPOUNDS ADMINISTERED TOGETHER WITH ANTI-CANCER AGENTS TO TREAT CANCER AND PHARMACEUTICAL COMPOSITIONS THEREOF | DOVETAIL TECHNOLOGIES INC. (US) | 1999-08-26 | — | — | WO | disclosed |
| US-5643878-A | TREATMENT OF RETROVIRAL DISEASES LIKE AIDS | CIBA-GEIGY CORPORATION (US) | 1997-07-01 | — | — | US | disclosed |
| US-5610315-A | Process for the preparation of 6,7-diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1997-03-11 | — | — | US | disclosed |
| US-5484954-A | HEATING, DEACYLATING | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1996-01-16 | — | — | US | disclosed |
| EP-0618222-A2 | Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid | CIBA-GEIGY AG (CH) | 1994-10-05 | — | — | EP | disclosed |
| US-5302730-A | Acylation with acetic acid at positions one and seven; eliminating acyl group at position seven by solvolysis | NIPPON KAYAKU KK (JP) | 1994-04-12 | — | — | US | disclosed |
| EP-0297496-B1 | Novel process for the preparation of 6,7-Diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KK (JP) | 1994-01-19 | — | — | EP | disclosed |
| EP-0297496-A2 | Novel process for the preparation of 6,7-Diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1989-01-04 | — | — | EP | disclosed |
| EP-0115227-B1 | PEPTIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1987-03-18 | — | — | EP | disclosed |
| US-4530837-A | Containing tryptophan | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1985-07-23 | — | — | US | disclosed |
| EP-0115227-A1 | Peptide derivatives, process for their preparation and their pharmaceutical use | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1984-08-08 | — | — | EP | disclosed |
| US-4183920-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1980-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | LMNA 1535/4885SMN1; SMN2 2439/4885HTT 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.